Gap play. NVAX is in stage 3 of a trial to treat influenza. This is a huge money maker. Net Income has been on a steady climb up. with a solid product this could take off. has broken the 200 day EMA for the first time in a long time. slight pull back at the moment.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.